Zacks Investment Research downgraded shares of International Stem Cell (OTCMKTS:ISCO) from a buy rating to a hold rating in a research note issued to investors on Wednesday.
According to Zacks, “International Stem Cell Corporation is a biotechnology company currently focused on developing therapeutic and research products. In the area of therapeutic product development, ISCO’s objective is to create an unlimited source of human cells for use in the treatment of several diseases, including diabetes, liver disease and retinal disease through cell transplant therapy. In furtherance of this objective, ISCO has developed pluripotent human stem cells from unfertilized human eggs, and techniques to cause those stem cells to be differentiated into the specific cell types required for transplant. It has developed manufacturing protocols to produce the cells minimizing contamination with animal by-products, a characteristic likely to be important in meeting U.S. Food and Drug Administration requirements. ISCO also provides the specialized cells and growth media needed for therapeutic cell transplantation research to academic and commercial researchers in related fields. “
ISCO opened at $1.52 on Wednesday. International Stem Cell has a 12-month low of $1.25 and a 12-month high of $1.90. The stock has a market cap of $10.75 million, a P/E ratio of -1.04 and a beta of -0.10.
International Stem Cell (OTCMKTS:ISCO) last posted its quarterly earnings results on Thursday, November 15th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter. The company had revenue of $3.20 million during the quarter. International Stem Cell had a negative net margin of 23.26% and a negative return on equity of 123.16%. Analysts forecast that International Stem Cell will post -0.32 earnings per share for the current year.
In other International Stem Cell news, CEO Andrey Semechkin acquired 599,222 shares of the company’s stock in a transaction dated Monday, January 21st. The shares were acquired at an average price of $1.75 per share, for a total transaction of $1,048,638.50. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 83.16% of the stock is owned by company insiders.
International Stem Cell Company Profile
International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes.
Featured Article: What is net income?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.